In vitroreactivation of latent HIV-1 by cytostatic bis(thiosemicarbazonate) gold(III) complexes

Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy

(2014) A. R. Cillo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV/AIDS eradication

(2013) Matthew D. Marsden et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

HIV Latency

(2013) R. F. Siliciano et al.   Cold Spring Harbor Perspectives in Medicine

Targeting HIV latency: pharmacologic strategies toward eradication

(2012) Sifei Xing et al.   DRUG DISCOVERY TODAY

Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension

(2011) Mark G. Lewis et al.   AIDS

New bis(thiosemicarbazonate) gold(III) complexes inhibit HIV replication at cytostatic concentrations: Potential for incorporation into virostatic cocktails

(2011) Pascaline N. Fonteh et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Activation of Latent HIV Using Drug-Loaded Nanoparticles

(2011) Michael Kovochich et al.   PLoS One

Physical and Functional HAT/HDAC Interplay Regulates Protein Acetylation Balance

(2010) Alessia Peserico et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection

(2009) Sophie Reuse et al.   PLoS One

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies

(2009) Laurence Colin et al.   Retrovirology

Gold complexes as potential anti-parasitic agents

(2008) Maribel Navarro   COORDINATION CHEMISTRY REVIEWS